NZ538793A - Eicosapentaenoic acid (EPA) for treating anorexia nervosa (AN) and bulimia - Google Patents
Eicosapentaenoic acid (EPA) for treating anorexia nervosa (AN) and bulimiaInfo
- Publication number
- NZ538793A NZ538793A NZ538793A NZ53879303A NZ538793A NZ 538793 A NZ538793 A NZ 538793A NZ 538793 A NZ538793 A NZ 538793A NZ 53879303 A NZ53879303 A NZ 53879303A NZ 538793 A NZ538793 A NZ 538793A
- Authority
- NZ
- New Zealand
- Prior art keywords
- epa
- use according
- medicament
- treatment
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0221480.7A GB0221480D0 (en) | 2002-09-16 | 2002-09-16 | Treatment of anorexia nervosa (AN) and bulimia |
| PCT/GB2003/003985 WO2004024136A1 (en) | 2002-09-16 | 2003-09-16 | Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ538793A true NZ538793A (en) | 2007-05-31 |
Family
ID=9944164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ538793A NZ538793A (en) | 2002-09-16 | 2003-09-16 | Eicosapentaenoic acid (EPA) for treating anorexia nervosa (AN) and bulimia |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060135608A1 (enExample) |
| EP (1) | EP1556028A1 (enExample) |
| JP (1) | JP2006503031A (enExample) |
| KR (1) | KR20050042823A (enExample) |
| CN (1) | CN1694694A (enExample) |
| AU (1) | AU2003269138A1 (enExample) |
| BR (1) | BR0317857A (enExample) |
| CA (1) | CA2499142A1 (enExample) |
| GB (1) | GB0221480D0 (enExample) |
| HR (1) | HRP20050245A2 (enExample) |
| IS (1) | IS7744A (enExample) |
| MX (1) | MXPA05002943A (enExample) |
| NO (1) | NO20051847L (enExample) |
| NZ (1) | NZ538793A (enExample) |
| PL (1) | PL375726A1 (enExample) |
| RS (1) | RS20050226A (enExample) |
| RU (1) | RU2330653C2 (enExample) |
| TW (1) | TW200410682A (enExample) |
| WO (1) | WO2004024136A1 (enExample) |
| ZA (1) | ZA200502161B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| EP1683519A4 (en) * | 2003-11-14 | 2009-04-01 | Mochida Pharm Co Ltd | PREVENTIVE / THERAPEUTIC AGENT FOR TREATING SPEECH DISORDERS |
| JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および／又はうつ症状の改善作用を有する組成物 |
| CN101631542B (zh) | 2006-12-28 | 2011-12-21 | 三得利控股株式会社 | 神经再生剂 |
| ES2561482T3 (es) | 2007-02-15 | 2016-02-26 | Centre De Recherche Sur Les Biotechnologies Marine | Monoglicéridos de ácido graso poliinsaturado, derivados, y sus usos |
| US8816110B2 (en) | 2007-02-15 | 2014-08-26 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| WO2008113177A1 (en) | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| EP3318255B1 (en) * | 2009-06-15 | 2021-03-10 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating stroke in a subject on concomitant statin therapy |
| BR112013020346A2 (pt) * | 2011-02-11 | 2019-09-24 | Du Pont | concentrado de ácido eicosapentaenoico, produto farmac~eutico, método de elaboração de um concentrado de ácido eicosapentaenoico e uso de óleo microbiano |
| US9447020B2 (en) | 2013-10-31 | 2016-09-20 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| RU2545988C1 (ru) * | 2013-11-12 | 2015-04-10 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы | Способ лечения хронического запора и функциональной анорексии |
| CN111971041A (zh) | 2018-02-07 | 2020-11-20 | Scf制药股份有限公司 | 多不饱和脂肪酸单甘油酯、组合物、方法及其用途 |
| WO2019204218A1 (en) * | 2018-04-16 | 2019-10-24 | Quadrant Biosciences Inc. | Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status |
| CA3054203C (en) | 2018-05-03 | 2021-01-05 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
| CN109276262B (zh) * | 2018-07-30 | 2021-01-26 | 中国科学院心理研究所 | 一种用于筛选高危进食障碍的检测系统 |
| US12226390B2 (en) | 2019-07-21 | 2025-02-18 | Scf Pharma Inc. | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| US12144786B2 (en) | 2020-03-27 | 2024-11-19 | Homeostasis Therapeutics LLC | Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9224809D0 (en) * | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
| US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
-
2002
- 2002-09-16 GB GBGB0221480.7A patent/GB0221480D0/en not_active Ceased
-
2003
- 2003-09-16 HR HR20050245A patent/HRP20050245A2/hr not_active Application Discontinuation
- 2003-09-16 CA CA002499142A patent/CA2499142A1/en not_active Abandoned
- 2003-09-16 EP EP03750919A patent/EP1556028A1/en not_active Ceased
- 2003-09-16 MX MXPA05002943A patent/MXPA05002943A/es not_active Application Discontinuation
- 2003-09-16 JP JP2004535695A patent/JP2006503031A/ja active Pending
- 2003-09-16 RS YUP-2005/0226A patent/RS20050226A/sr unknown
- 2003-09-16 PL PL03375726A patent/PL375726A1/xx not_active Application Discontinuation
- 2003-09-16 NZ NZ538793A patent/NZ538793A/en unknown
- 2003-09-16 AU AU2003269138A patent/AU2003269138A1/en not_active Abandoned
- 2003-09-16 TW TW092125483A patent/TW200410682A/zh unknown
- 2003-09-16 US US10/528,114 patent/US20060135608A1/en not_active Abandoned
- 2003-09-16 RU RU2005107416/14A patent/RU2330653C2/ru not_active IP Right Cessation
- 2003-09-16 KR KR1020057004483A patent/KR20050042823A/ko not_active Withdrawn
- 2003-09-16 BR BR0317857-9A patent/BR0317857A/pt not_active IP Right Cessation
- 2003-09-16 WO PCT/GB2003/003985 patent/WO2004024136A1/en not_active Ceased
- 2003-09-16 CN CNA038251698A patent/CN1694694A/zh active Pending
-
2005
- 2005-03-15 ZA ZA200502161A patent/ZA200502161B/en unknown
- 2005-03-15 IS IS7744A patent/IS7744A/is unknown
- 2005-04-15 NO NO20051847A patent/NO20051847L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0317857A (pt) | 2005-12-06 |
| JP2006503031A (ja) | 2006-01-26 |
| US20060135608A1 (en) | 2006-06-22 |
| EP1556028A1 (en) | 2005-07-27 |
| PL375726A1 (en) | 2005-12-12 |
| TW200410682A (en) | 2004-07-01 |
| WO2004024136A1 (en) | 2004-03-25 |
| CA2499142A1 (en) | 2004-03-25 |
| RU2330653C2 (ru) | 2008-08-10 |
| NO20051847L (no) | 2005-04-15 |
| RU2005107416A (ru) | 2006-01-20 |
| MXPA05002943A (es) | 2005-06-03 |
| CN1694694A (zh) | 2005-11-09 |
| ZA200502161B (en) | 2005-09-15 |
| GB0221480D0 (en) | 2002-10-23 |
| AU2003269138A1 (en) | 2004-04-30 |
| RS20050226A (sr) | 2007-09-21 |
| KR20050042823A (ko) | 2005-05-10 |
| IS7744A (is) | 2005-03-15 |
| HRP20050245A2 (en) | 2005-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060135608A1 (en) | Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia | |
| Drabińska et al. | Recent advances in the application of a ketogenic diet for obesity management | |
| JP5064609B2 (ja) | β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法 | |
| CN103338762A (zh) | 血糖值上升抑制剂 | |
| CN103298462A (zh) | 降低暴食或强迫进食的方法 | |
| JP7294147B2 (ja) | 侵害受容性疼痛の予防又は改善用組成物 | |
| JP6360172B2 (ja) | チグリンアルデヒドを使用する組成物及び方法 | |
| JP6368368B2 (ja) | ｐ−アニスアルデヒドを使用する組成物及び方法 | |
| Alshaikh et al. | Long-term follow-up of patients with narcolepsy-cataplexy treated with sodium oxybate (Xyrem) | |
| CN102085357B (zh) | 原料含有水蛭素、纤溶素的药物的用途 | |
| Dighikar et al. | A Rare Case of Wilson’s Disease in a 17 Years Old Girl | |
| CN116963728A (zh) | 用草酰乙酸酯治疗病理性疲劳 | |
| US20040192781A1 (en) | Method of administration for metoclopramide and pharmaceutical formulation therefor | |
| JP2016525133A (ja) | クミンアルデヒドを使用する組成物及び方法 | |
| EP3389666A1 (en) | Compositions comprising 3'-o-glucuronide epicatechin and methods of making and using such compositions | |
| JP6143215B2 (ja) | 高脂肪食への嗜好性を軽減させるための医薬組成物、飲食品組成物または飲食品添加剤 | |
| do Espírito Santo et al. | Graves’ Disease and Down Syndrome: Case Report | |
| EP1964558A1 (en) | Pharmaceutical compositions containing intestinal lipase inhibiting substances combined with a chromium dinicotinate o-coordinated complex for use in the treatment and control of obesity and overweight | |
| Cicero et al. | Complementary and Alternative Medicine for Hypertension: What Evidence is There for Herbalist Suggestions? | |
| Myers | Thyroid Disorders | |
| Blanchette | Prevention of the disease of aging | |
| Saneie et al. | Application of low phenylalanine products in the diet of children with phenylketonuria | |
| Impairment | LANTUS® | |
| CN108367014A (zh) | 包含4’-o-葡糖苷酸表儿茶素的组合物以及制备和使用此类组合物的方法 | |
| JP2005272368A (ja) | ビタミンＥ及びβ−カロテンを用いるＴｈ１／Ｔｈ２バランス調節剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed |